EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
By Ali Canbay, V. Nobili, V. Ratziu, Herbert Tilg, Amalia Gastaldelli, Hannele Yki-Järvinen, G. Frühbeck, L. Mathus-vliegen. Obesity Facts, 2016
3,531 citations recorded by the source corpus.
The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference [1] . The data have been retrieved by an extensive PubMed search up to April 2015. The final statements are graded according to the level of evidence and strength of recommendation, which are adjustable to local regulations and/or team capacities ( table 1 ) [2] . In particular, screening for NAFLD in the population at risk should be in the context of the available resources, considering the burden for the national healthcare systems and the currently limited effective treatments. The document is intended both for practical use and for advancing the research and knowledge of NAFLD in adults, with specific reference to paediatric NAFLD, whenever necessary. The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system. Received: November 4, 2015 Accepted: November 4, 2015 Published online: April 8, 2016
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/3e105ffce2a25ab4d4a74418bda08bbb342472c5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
- Z. Younossi
- M. Rinella
- K. Cusi
- Hannele Yki-Järvinen
- E. Tsochatzis
- Christopher D. Byrne
- L. Adams
- J. Shaw
In Epidemiology
In Hepatology
Citations in the corpus
- Epidemiology of metabolic dysfunction-associated steatotic liver disease (2024, positive): “[26-29] Lean MASLD Although obesity, as discussed previously, is one of the most common metabolic comorbidities present in those with MASLD, individuals can also have what has been termed lean MASLD where the body mass index (BMI) falls within the normal range but yet SLD may be present.”